Literature DB >> 8528251

Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene.

V De Laurenzi1, G R Rogers, D J Hamrock, L N Marekov, P M Steinert, J G Compton, N Markova, W B Rizzo.   

Abstract

Sjögren-Larsson syndrome (SLS) is an inherited neurocutaneous disorder characterized by mental retardation, spasticity and ichthyosis. SLS patients have a profound deficiency in fatty aldehyde dehydrogenase (FALDH) activity. We have now cloned the human FALDH cDNA and show that it maps to the SLS locus on chromosome 17p11.2. Sequence analysis of FALDH amplified from fibroblast mRNA and genomic DNA from 3 unrelated SLS patients reveals distinct mutations, including deletions, an insertion and a point mutation. The cloning of FALDH and the identification of mutations in SLS patients opens up possibilities for developing therapeutic approaches to ameliorate the neurologic and cutaneous symptoms of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8528251     DOI: 10.1038/ng0196-52

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  56 in total

1.  Molecular basis of Sjögren-Larsson syndrome: frequency of the 1297-1298 del GA and 943C-->T mutation in 29 patients.

Authors:  L Ijlst; W Oostheim; M van Werkhoven; M A Willemsen; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  Sjögren-Larsson syndrome in Brazil is caused by a common c.1108-1G-->C splice-site mutation in the ALDH3A2 gene.

Authors:  M P Auada; M B Puzzi; M L Cintra; C E Steiner; F Alexandrino; E L Sartorato; T S Aguiar; R D Azulay; G Carney; W B Rizzo
Journal:  Br J Dermatol       Date:  2006-04       Impact factor: 9.302

3.  Design, synthesis, and ex vivo evaluation of a selective inhibitor for retinaldehyde dehydrogenase enzymes.

Authors:  Angelica R Harper; Anh T Le; Timothy Mather; Anthony Burgett; William Berry; Jody A Summers
Journal:  Bioorg Med Chem       Date:  2018-10-24       Impact factor: 3.641

4.  Large contiguous gene deletions in Sjögren-Larsson syndrome.

Authors:  Holly Engelstad; Gael Carney; Dana S'aulis; Janae Rise; Warren G Sanger; M Katharine Rudd; Gabriele Richard; Christopher W Carr; Omar A Abdul-Rahman; William B Rizzo
Journal:  Mol Genet Metab       Date:  2011-05-30       Impact factor: 4.797

Review 5.  Pure hereditary spastic paraplegia.

Authors:  E Reid
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

6.  Exon/intron structure of aldehyde dehydrogenase genes supports the "introns-late" theory.

Authors:  A Rzhetsky; F J Ayala; L C Hsu; C Chang; A Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

7.  Genome-wide analyses identify common variants associated with macular telangiectasia type 2.

Authors:  Thomas S Scerri; Anna Quaglieri; Carolyn Cai; Jana Zernant; Nori Matsunami; Lisa Baird; Lea Scheppke; Roberto Bonelli; Lawrence A Yannuzzi; Martin Friedlander; Catherine A Egan; Marcus Fruttiger; Mark Leppert; Rando Allikmets; Melanie Bahlo
Journal:  Nat Genet       Date:  2017-02-27       Impact factor: 38.330

Review 8.  Pathogenesis-based therapies in ichthyoses.

Authors:  Joey E Lai-Cheong; Peter M Elias; Amy S Paller
Journal:  Dermatol Ther       Date:  2013 Jan-Feb       Impact factor: 2.851

9.  Homozygosity mapping of a locus for a novel syndromic ichthyosis to chromosome 3q27-q28.

Authors:  Lekbir Baala; Smaïl Hadj-Rabia; Dominique Hamel-Teillac; Michelle Hadchouel; Catherine Prost; Suzanne M Leal; Emmanuel Jacquemin; Abdelaziz Sefiani; Yves De Prost; Gilles Courtois; Arnold Munnich; Stanislas Lyonnet; Pierre Vabres
Journal:  J Invest Dermatol       Date:  2002-07       Impact factor: 8.551

10.  Ichthyosis in Sjögren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion.

Authors:  William B Rizzo; Dana S'Aulis; M Anitia Jennings; Debra A Crumrine; Mary L Williams; Peter M Elias
Journal:  Arch Dermatol Res       Date:  2010-01-05       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.